Important note: Information in this article was accurate in 2005. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 2005. The state of the art may have changed since the publication date.
Reuters NewMedia - November 14, 2005
The trials will test the safety of tgAAC09, a vaccine candidate that is based on the HIV sub-type most prevalent in southern and eastern Africa, the two groups said in a joint statement on Monday.
Sub-Saharan Africa is the region hardest hit by AIDS, with more than 25 million people estimated to be infected with HIV, the virus that leads to the disease.
South Africa has the highest caseload of HIV in the world, with about one in nine of its 45 million population carrying the virus, while in neighbouring Botswana and Swaziland prevalence is as high as 40 percent.
"We are pleased that South Africa has taken a leading role in the testing of vaccine candidates given the medical and humanitarian promise a preventative vaccine holds," said Eftyhia Vardas, a doctor at the country's Perinatal HIV Research Unit, who will coordinate the trials.
Investigators test the immune response and acquire more data on safety during second phase trials on drugs that have already been proven safe during first phase tests.
The vaccine candidate, developed by U.S.-based Targeted Genetics, will be tested on 78 volunteers at three sites in South Africa. The trial is expected to last 18 months.
IAVI, a global non-profit organization working to accelerate the development of an AIDS vaccine, estimates that around 30 preventative HIV vaccine candidates are in human trials.
051114
RE051113
Copyright © 2005 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .